MAGE-3 (119-134)

MAGE-3 (119-134) is a synthetic peptide fragment derived from the melanoma-associated antigen 3 (MAGE-3) protein, a member of the MAGE family known for its restricted expression in various tumor cells and limited presence in normal tissues. The sequence corresponding to amino acids 119 through 134 of MAGE-3 has been widely utilized in immunological research, particularly in studies focused on tumor antigenicity and immune recognition. As a defined peptide epitope, it serves as a valuable molecular tool for dissecting T-cell responses, antigen processing, and presentation mechanisms, making it highly relevant for researchers investigating tumor immunology, antigen-specific cellular assays, and peptide-based functional studies.

Epitope mapping: The MAGE-3 (119-134) peptide is commonly employed in epitope mapping experiments to delineate the precise regions of the MAGE-3 protein recognized by T lymphocytes. By incorporating this peptide into in vitro assays, researchers can identify specific CD4+ or CD8+ T-cell epitopes, facilitating the characterization of antigen-specific immune responses. Such studies are instrumental in advancing the understanding of tumor antigen presentation and the development of immunotherapeutic strategies targeting cancer-associated antigens.

T-cell activation assays: In immunological research, this peptide serves as a defined stimulus for evaluating the activation, proliferation, and cytokine production of antigen-specific T cells. It can be loaded onto antigen-presenting cells or used to pulse dendritic cells in culture, enabling precise assessment of T-cell receptor (TCR) recognition and the functional capacity of immune effector cells. These assays provide critical insights into immune surveillance mechanisms and the cellular basis of anti-tumor immunity.

Peptide-MHC binding studies: The defined sequence of MAGE-3 (119-134) is suitable for peptide-major histocompatibility complex (MHC) binding assays, where it is used to analyze the affinity and stability of peptide-MHC complexes. Such studies are essential for understanding the molecular determinants of antigen presentation by class I or class II MHC molecules, as well as for predicting immunogenicity and optimizing epitope design in immunological applications.

Vaccine research models: As a well-characterized tumor-associated peptide, MAGE-3 (119-134) is frequently incorporated into experimental vaccine platforms and in vitro immunization protocols. It enables the evaluation of antigen-specific immune priming, the generation of memory responses, and the assessment of adjuvant efficacy. The use of this peptide in preclinical models supports the rational design and optimization of peptide-based immunogens for cancer research and immunotherapy development.

Analytical peptide studies: Beyond immunological applications, the MAGE-3 (119-134) peptide can be utilized as a reference standard or analytical reagent in peptide characterization workflows. Its defined sequence and synthetic origin make it suitable for mass spectrometry calibration, peptide quantification, and method validation in proteomics or quality control laboratories. Such applications contribute to the standardization and reproducibility of peptide analysis in research and development settings.

1. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet

2. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

3. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

4. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum

5. Implications of ligand-receptor binding kinetics on GLP-1R signalling